The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab

Kaneshiro, Shoichi; Ebina, Kosuke; Hirao, Makoto; Tsuboi, Hideki; Nishikawa, Masataka; Nampei, Akihide; Nagayama, Yoshio; Takahi, Koichiro; Noguchi, Takaaki; Owaki, Hajime; Hashimoto, Jun; Yoshikawa, Hideki

doi:https://doi.org/10.1080/14397595.2016.1181315

The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab

Kaneshiro, Shoichi; Ebina, Kosuke; Hirao, Makoto et al.

Modern Rheumatology, 2017, 27(1), 42-49

アクセス数:963件（2025-07-17 14:44 集計）

固定URL: https://hdl.handle.net/11094/93266

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
ModRheumatol_27_1_42	pdf	なし	860 KB	62	2023.12.07

Creative Commons : 表示 - 非営利

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab
著者	著者名 Kaneshiro, Shoichi
	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 著者名 Ebina, Kosuke
	NRID 1000010527708 1000010527708 著者名 Hirao, Makoto
	著者名 Tsuboi, Hideki
	著者名 Nishikawa, Masataka
	NRID 1000070464245 1000070464245 著者名 Nampei, Akihide
	著者名 Nagayama, Yoshio
	著者名 Takahi, Koichiro
	NRID 1000050812294 1000050812294 researchmap permalink takaakinoguchi takaakinoguchi ORCID 0000-0001-9938-6780 0000-0001-9938-6780 著者名 Noguchi, Takaaki
	NRID 1000060223872 1000060223872 著者名 Owaki, Hajime
	NRID 1000040237938 1000040237938 著者名 Hashimoto, Jun
	NRID 1000060191558 1000060191558 著者名 Yoshikawa, Hideki
キーワード等	Biologics
	Inadequate response
	Rheumatoid arthritis
	Tacrolimus
	Tocilizumab
内容	Kaneshiro S., Ebina K., Hirao M., et al. The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab. Modern Rheumatology 27, 42 (2017); https://doi.org/10.1080/14397595.2016.1181315.
抄録	Objectives: Tocilizumab (TCZ) shows good retention in patients with rheumatoid arthritis (RA), but no previous reports demonstrated hopeful treatment options against inadequate response to TCZ. Tacrolimus (TAC) has proved to show efficacy against inadequate response to tumor necrosis factor alpha inhibitors, yet its add-on effects on TCZ remain unknown. Methods: Twenty patients with RA (17 women, age 58.6 years, disease duration 12.1 years, prior TCZ duration 2.6 years, 18 intravenous [8 mg/kg/month] and 2 subcutaneous [324 mg/month] TCZ treatments, methotrexate 6.1 mg/week [70.0%]) who showed an inadequate response to TCZ (clinical disease activity index [CDAI] ≥ 5.8, 18 secondary non-responders) were additionally treated with TAC (1.1 mg/day), and enrolled in this 24-week, prospective study. Results: Seventeen patients (85.0%) continued the treatment for 24 weeks. Statistically significant decreases in outcome measures were as follows: disease activity score based on 28 joints with C-reactive protein (DAS28-CRP) from 3.3 at baseline to 2.1 at week 24 (p < 0.001), CDAI from 17.7 to 7.6 (p < 0.001), and serum matrix metalloproteinase-3 levels from 232.8 to 66.2 ng/ml (p < 0.001). About 15 patients (75%) achieved low disease activity or remission (DAS28-CRP ≤2.7 or CDAI ≤10) at week 24. Conclusions: Adding low-dose TAC to inadequate responders to TCZ may be a promising complementary treatment option.
出版者	Taylor and Francis Ltd
収録物名	Modern Rheumatology
巻(号)	27(1)
ページ	42-49
刊行年月	2017-01-02
言語	英語
ハンドルURL	https://hdl.handle.net/11094/93266
PISSN	14397595
eISSN	14397609
関連情報 (isVersionOf)	DOI (出版社版) https://doi.org/10.1080/14397595.2016.1181315
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
出版タイプ	Accepted Manuscript
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Modern Rheumatology. 2017, 27(1), p. 42-49
DC.title	The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab
DC.creator	Kaneshiro, Shoichi
	Ebina, Kosuke
	Hirao, Makoto
	Tsuboi, Hideki
	Nishikawa, Masataka
	Nampei, Akihide
	Nagayama, Yoshio
	Takahi, Koichiro
	Noguchi, Takaaki
	Owaki, Hajime
	Hashimoto, Jun
	Yoshikawa, Hideki
DC.publisher	Taylor and Francis Ltd
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2017-01-02
DC.identifier	https://doi.org/10.1080/14397595.2016.1181315
DC.subject	Biologics
	Inadequate response
	Rheumatoid arthritis
	Tacrolimus
	Tocilizumab
DC.description	Kaneshiro S., Ebina K., Hirao M., et al. The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab. Modern Rheumatology 27, 42 (2017); https://doi.org/10.1080/14397595.2016.1181315.
DCTERMS.abstract	Objectives: Tocilizumab (TCZ) shows good retention in patients with rheumatoid arthritis (RA), but no previous reports demonstrated hopeful treatment options against inadequate response to TCZ. Tacrolimus (TAC) has proved to show efficacy against inadequate response to tumor necrosis factor alpha inhibitors, yet its add-on effects on TCZ remain unknown. Methods: Twenty patients with RA (17 women, age 58.6 years, disease duration 12.1 years, prior TCZ duration 2.6 years, 18 intravenous [8 mg/kg/month] and 2 subcutaneous [324 mg/month] TCZ treatments, methotrexate 6.1 mg/week [70.0%]) who showed an inadequate response to TCZ (clinical disease activity index [CDAI] ≥ 5.8, 18 secondary non-responders) were additionally treated with TAC (1.1 mg/day), and enrolled in this 24-week, prospective study. Results: Seventeen patients (85.0%) continued the treatment for 24 weeks. Statistically significant decreases in outcome measures were as follows: disease activity score based on 28 joints with C-reactive protein (DAS28-CRP) from 3.3 at baseline to 2.1 at week 24 (p < 0.001), CDAI from 17.7 to 7.6 (p < 0.001), and serum matrix metalloproteinase-3 levels from 232.8 to 66.2 ng/ml (p < 0.001). About 15 patients (75%) achieved low disease activity or remission (DAS28-CRP ≤2.7 or CDAI ≤10) at week 24. Conclusions: Adding low-dose TAC to inadequate responders to TCZ may be a promising complementary treatment option.
DC.rights	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
DC.format	93266
citation_title	The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab
citation_author	Kaneshiro, Shoichi
	Ebina, Kosuke
	Hirao, Makoto
	Tsuboi, Hideki
	Nishikawa, Masataka
	Nampei, Akihide
	Nagayama, Yoshio
	Takahi, Koichiro
	Noguchi, Takaaki
	Owaki, Hajime
	Hashimoto, Jun
	Yoshikawa, Hideki
citation_publisher	Taylor and Francis Ltd
citation_language	英語
citation_date	2017-01-02
citation_journal_title	Modern Rheumatology
citation_volume	27
citation_issue	1
citation_firstpage	42
citation_lastpage	49
citation_doi	https://doi.org/10.1080/14397595.2016.1181315
citation_public_url	https://hdl.handle.net/11094/93266

The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab

閲覧可能ファイル

論文情報

論文詳細を表示